Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to see if pegfilgrastim (Neulasta) is safe and useful in
supporting people through dose-dense chemotherapy, and to see if a long-acting red blood cell
growth factor, darbepoetin alfa(Aranesp) can reduce the need for blood transfusion in
chemotherapy recipients.
Phase:
Phase 2
Details
Lead Sponsor:
Harold J. Burstein, MD, PhD
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Dana-Farber Cancer Institute Lowell General Hospital Massachusetts General Hospital North Shore Medical Center